Edition:
United Kingdom

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

6.78USD
15 Nov 2018
Change (% chg)

$0.62 (+10.06%)
Prev Close
$6.16
Open
$6.19
Day's High
$6.78
Day's Low
$6.19
Volume
751
Avg. Vol
5,511
52-wk High
$11.41
52-wk Low
$4.80

Latest Key Developments (Source: Significant Developments)

Arcturus Therapeutics Q3 Loss Per Share $0.42
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.42.  Full Article

Arcturus Therapeutics Q2 Loss Per Share $0.99
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.99.CASH, CASH EQUIVALENTS, & INVESTMENTS TOTALED $39.8 MILLION AS OF JUNE 30, 2018.APPOINTED ANDREW SASSINE AS INTERIM CHIEF FINANCIAL OFFICER, EFFECTIVE AUGUST 24, 2018.REVENUE OF $2.4 MILLION, COMPARED WITH $3.8 MILLION DURING Q2 OF 2017.  Full Article

Arcturus Says Founder Joseph Payne Reinstated As President And CEO
Thursday, 31 May 2018 

May 31 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS ANNOUNCES MANAGEMENT APPOINTMENTS; COMPANY FOUNDER JOSEPH E. PAYNE REINSTATED AS PRESIDENT AND CEO.ARCTURUS THERAPEUTICS LTD - PAD CHIVUKULA HAS BEEN REINSTATED AS CHIEF SCIENTIFIC OFFICER AND CHIEF OPERATING OFFICER.ARCTURUS THERAPEUTICS LTD - PETER FARRELL HAS BEEN NAMED AS CHAIRMAN OF BOARD OF DIRECTORS OF COMPANY.  Full Article

Amir Efrati Reports 5.3 Percent Stake In Arcturus Therapeutics
Monday, 30 Apr 2018 

April 30 (Reuters) - Arcturus Therapeutics Ltd ::AMIR EFRATI - ON APRIL 27, SENT LETTER TO ISRAELI COURT SHOWING OPPOSITION TO TRANSACTION THEY BELIEVE ARCTURUS THERAPEUTICS BOARD HAS BEEN PURSUING.AMIR EFRATI REPORTS 5.3 PERCENT STAKE IN ARCTURUS THERAPEUTICS AS OF APRIL 27, 2018 - SEC FILING.AMIR EFRATI SAYS INTEND TO REVIEW INVESTMENT IN ARCTURUS THERAPEUTICS ON A CONTINUING BASIS.AMIR EFRATI SAYS PURCHASED ARCTURUS THERAPEUTICS' SHARES BASED ON BELIEF THAT SHARES, WHEN PURCHASED, WERE UNDERVALUED.  Full Article

Joseph Payne Says "Rejects" Arcturus Therapeutics' Board Of Directors' Latest Lawsuit Against Payne
Monday, 23 Apr 2018 

April 23 (Reuters) - Arcturus Therapeutics Ltd ::JOSEPH PAYNE SAYS "REJECTS" ARCTURUS THERAPEUTICS' BOARD OF DIRECTORS' LATEST LAWSUIT AGAINST PAYNE.JOSEPH PAYNE SAYS OWNS APPROXIMATELY 13.7% OF ISSUED AND OUTSTANDING SHARES OF ARCTURUS THERAPEUTICS.JOSEPH PAYNE SAYS URGES ARCTURUS THERAPEUTICS' BOARD TO SET DATE FOR THE EXTRAORDINARY GENERAL MEETING THAT PAYNE FILED FORMAL REQUEST FOR ON FEB 12.  Full Article

Bradley Thomas Sorenson Reports 5.6 Pct Stake In Arcturus Therapeutics As Of Nov. 16, 2017
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Bradley Thomas Sorenson: :BRADLEY THOMAS SORENSON REPORTS 5.6 PERCENT STAKE IN ARCTURUS THERAPEUTICS LTD AS OF NOVEMBER 16, 2017 - SEC FILING.BRADLEY THOMAS SORENSON - PURCHASED ARCTURUS THERAPEUTICS' SHARES BASED ON BELIEF THAT SUCH SECURITIES, WHEN PURCHASED, WERE "UNDERVALUED".  Full Article

Arcturus Announces Expansion Of Collaboration With Takeda
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES EXPANSION OF COLLABORATION WITH TAKEDA PHARMACEUTICALS TO DEVELOP RNA-BASED THERAPEUTICS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) AND OTHER GI DISORDERS.ARCTURUS THERAPEUTICS - TAKEDA, CO TO DEVELOP RNA-BASED THERAPEUTICS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, OTHER GASTROINTESTINAL.ARCTURUS - TO DEVELOP TREATMENT OF NASH AND GI RELATED DISORDERS USING CO'S LUNAR LIPID-MEDIATED DELIVERY SYSTEMS & UNA OLIGOMER CHEMISTRY.  Full Article

Arcturus and Curevac Enter Into Strategic Collaboration To Jointly Novel Messenger RNA Therapeutics
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Arcturus Therapeutics Ltd ::CO, CUREVAC AG ENTER INTO STRATEGIC COLLABORATION TO JOINTLY DISCOVER, DEVELOP,COMMERCIALIZE NOVEL MESSENGER RNA THERAPEUTICS.DEVELOPMENT COSTS WILL BE SHARED BETWEEN COS,WITH PLANS TO CO-COMMERCIALIZE PRODUCTS IN FUTURE UNDER PROFIT SHARING ARRANGEMENT.  Full Article

Arcturus Therapeutics Ltd Says Raised About $67.8 Million In Equity Financing
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS LTD SAYS RAISED ABOUT $67.8 MILLION IN EQUITY FINANCING .  Full Article

Alcobra qtrly ‍net loss per share $0.09​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Alcobra Ltd :Alcobra announces third quarter 2017 financial results and provides corporate update.Alcobra Ltd - qtrly ‍net loss per share $0.09​.  Full Article